Measuring the Effectiveness of a New Blood Cancer Treatment Approach
NCT07451054 · RecruitingThis trial looks at a new approach to treat certain blood cancers. It studies a combination of two types of cells: anti-CD45 CAR T cells and CD45 base edited stem cells. The goal is to find out how safe and effective this treatment is for patients with blood cancers that have not responded to other therapies.
Locations and contact
This trial is running at 1 location in the United States. It is currently recruiting.
United States1 location · 1 recruiting
- University of PennsylvaniaPhiladelphia, PennsylvaniaRecruiting
Who can join
Adults aged 18 and older, both men and women, can join the trial. Participants must have specific types of relapsed or resistant blood cancers, such as B-cell or T-cell non-Hodgkin lymphoma, Hodgkin lymphoma, or Richter's transformation. They should have already tried at least two different types of treatment without success. The trial team will confirm who is eligible.
What happens during the trial
Participants will be placed into different groups. One group will focus on treating B-cell non-Hodgkin lymphoma and Richter's transformation. The other group will focus on T-cell non-Hodgkin lymphoma and Hodgkin lymphoma. Everyone in the trial will receive the new treatment, which includes specialized CAR T cells and edited stem cells.
The trial team
The trial is run by the University of Pennsylvania, with collaboration from Kite, a Gilead Company. Dr. Noelle Frey is the principal investigator leading the study.
Important dates
The trial started in July 2026 and is expected to finish in July 2051. It is currently enrolling new participants.
Additional information
The trial's ID is NCT07451054. It is in Phase 1, which means it is looking at how well the new treatment works and how safe it is. This trial is FDA-regulated and aims to include 42 participants.
Other recruiting trials for the same condition, with the eligibility rules written in plain language.
Browse similar trials →Find a top oncologist who can tell you whether a trial is a sensible option for you.
Find a doctor →The cancer centers running studies like this one, and what each is known for.
Browse hospitals →